Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. Financial performance shows a decrease in cash and interest income, but strategic currency shifts and stable income from royalties are positives. The Q&A highlights a focus on strategic partnerships, particularly with Gilead, but lacks clarity on deal specifics and internal pipeline strategies. The absence of strong guidance or new partnership announcements tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Key Financial Performance
Total operating loss from continuing operations (9 months 2025) EUR 462.2 million, compared to EUR 125.6 million for the first 9 months of 2024. The increase was due to an impairment on the cell therapy business of EUR 204.8 million and a EUR 135.5 million impact related to the strategic reorganization announced in January 2025.
Net other financial income (9 months 2025) EUR 30.4 million, compared to EUR 71.7 million for the first 9 months of 2024. The decrease was due to a reduction in interest income from EUR 70.6 million in 2024 to EUR 31.4 million in 2025, attributed to lower interest rates and a shift in investment strategy.
Fair value gains and interest income (9 months 2025) EUR 77.2 million, derived from cash, cash equivalents, and current financial investments, excluding currency exchange rate impact.
Financial investments, cash, and cash equivalents (as of September 30, 2025) EUR 3.05 billion, compared to EUR 3.32 billion on December 31, 2024. The decrease reflects ongoing operational and strategic expenses.
Cash and cash equivalents and current financial investments in U.S. dollars (as of September 30, 2025) $2.16 billion, compared to $726.9 million on December 31, 2024. The increase was due to a strategic shift in currency holdings.
Interest income (9 months 2025) EUR 31.4 million, compared to EUR 70.6 million for the first 9 months of 2024. The decline was due to lower interest rates and a shift from term deposits to money market funds.
Income from Jyseleca royalties and earn-outs Approximately EUR 15 million to EUR 20 million annually, expected to continue into the mid-2030s with potential upside.
Tax receivables (next 3 years) Approximately EUR 20 million to EUR 35 million per year, with additional opportunities for credits beyond that.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TYK2 Program: The TYK2 program is progressing with Phase III enabling studies for GLPG3667, an oral TYK2 inhibitor. Data from two studies are expected by early 2026, ahead of schedule. The program has shown differentiation from other TYK2 inhibitors and potential for significant value.
Business Development Strategy: Galapagos is focusing on clinically derisked and differentiated opportunities that enhance the standard of care. The company is leveraging its partnership with Gilead to explore joint acquisitions, licensing, and other creative deal structures.
Cell Therapy Business Wind Down: The company plans to wind down its cell therapy business after failing to find viable buyers or investors. This decision impacts approximately 365 employees and involves closing sites in Europe, the U.S., and China. The process is expected to conclude by Q1 2026.
Financial Position: Galapagos has a cash balance of approximately EUR 3 billion, generating significant interest income. The company expects to end 2025 with EUR 2.975 billion to EUR 3.05 billion in cash and investments, excluding business development activities.
Company Transformation: Galapagos is undergoing a transformation, focusing on business development and rebuilding its pipeline. The company has assembled a new leadership team and strategic advisory board to drive this change.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Spin-off failure and strategic alternatives: The planned spin-off of the cell therapy business could not be executed as planned, leading to a strategic review and sale process. Despite efforts, no viable proposals were presented to support the business, resulting in the decision to wind down the cell therapy business. This failure highlights challenges in executing strategic initiatives and finding suitable buyers or investors.
Significant investment requirements: The cell therapy business requires hundreds of millions of euros in ongoing investments, including obligations to employees. This financial burden has made it difficult to find buyers or investors, impacting the company's ability to sustain this business.
Employee and operational impact: The wind-down of the cell therapy business is expected to impact approximately 365 employees across multiple global offices and lead to the closure of sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai. This could disrupt operations and employee morale.
Market dynamics and financial strain: Evolving market dynamics and the financial strain of maintaining the cell therapy business have contributed to the decision to wind down operations, reflecting challenges in adapting to market conditions.
Regulatory and legal hurdles: The wind-down process is subject to consultations with works councils in Belgium and the Netherlands, which could delay implementation and create uncertainty.
Financial losses and impairments: The company reported an operating loss of EUR 462.2 million for the first 9 months of 2025, including a EUR 204.8 million impairment on the cell therapy business and EUR 135.5 million in strategic reorganization costs. These losses highlight financial challenges.
Dependence on partnerships: The company’s reliance on partnerships, such as with Gilead, for business development and financial support could limit its strategic flexibility and create dependency risks.
Uncertain future pipeline: While the company is focusing on business development and rebuilding its pipeline, the success of these efforts remains uncertain, posing risks to long-term growth and innovation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cell Therapy Business Wind Down: Galapagos intends to wind down its cell therapy business following consultations with works councils in Belgium and the Netherlands. The process is expected to conclude in Q1 2026. If implemented, up to 365 employees will be impacted, and sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai will be closed. The company will consider any viable acquisition proposals during the wind-down process.
TYK2 Program: The Phase III enabling studies for the TYK2 program are progressing ahead of schedule, with data expected by early 2026. The program focuses on GLPG3667, a differentiated oral TYK2 inhibitor for SLE and dermatomyositis. Results from these studies will guide the next steps for the program.
Financial Guidance: Galapagos anticipates ending 2025 with approximately EUR 2.975 billion to EUR 3.05 billion in cash, excluding business development activities and currency fluctuations. The company expects to be cash flow neutral to positive by the end of 2026, following the wind-down of the cell therapy business.
Business Development Strategy: Galapagos plans to focus on clinically derisked and differentiated opportunities that enhance the standard of care. The company aims to leverage its partnership with Gilead for joint acquisitions or licensing opportunities, with a focus on areas of strategic synergy. Financial discipline and value creation will be key priorities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash Balance: Our cash balance of approximately EUR 3 billion represents approximately EUR 46 per share. This cash balance generates significant interest income. Through the first 9 months of this year alone, we received approximately EUR 77 million.
Income from Jyseleca: In addition, we are receiving an attractive stream of royalties and earn-outs from Gilead and Alfasigma on their sales of Jyseleca, the JAK program developed here at Galapagos. The income related to Jyseleca has been approximately EUR 15 million to EUR 20 million annually and is expected to continue into the mid-2030s with potential upside.
Tax Receivables: In addition, we expect to receive tax receivables of approximately EUR 20 million to EUR 35 million per year over the next 3 years with additional opportunities for credits beyond that.
Shareholder Return: Many investors have asked us whether we will return capital to shareholders. While our goal is ultimately to drive value for our shareholders, it's important to recognize that any return of capital would require alignment with Gilead given their 25% ownership and the terms of our existing partnership agreement with them. In addition, even as permitted, Belgium law imposes certain limitations on capital returns to shareholders. Given we do not have any distributable profits available at the current time, the ability to distribute would require a resolution at an EGM with at least 50% of shares present at the meeting and at least 75% approval. So again, while this could be an interesting alternative down the road, for now, we are focused on using our capital for business development opportunities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What assumptions go into achieving cash flow neutral to positive status by year-end 2026?
A:The assumptions include interest income based on forward curve and cash balance, no BD activity, income from Jyseleca, tax credits from Belgium and other countries, and completion of the works council process and wind down.
Q:What kinds of opportunities are in the deal funnel and the level of optimism around them?
A:The focus is on clinically derisked mid- to late-stage opportunities, including M&A and partnerships. The therapeutic areas of interest are oncology and immunology/inflammatory disease, with a priority to collaborate with Gilead on deals.
Q:How does the company balance being conservative and achieving cash flow positive status versus pursuing BD?
A:The company focuses on leveraging existing assets like cash balance, royalty streams, and tax benefits to achieve cash flow positive status while seeking opportunities that create a positive return on cash balance.
Q:What are the expectations for Gilead's contribution to the deal process?
A:Gilead contributes through diligence expertise, offering capital, and leveraging their infrastructure for development. The collaboration can take many forms beyond the current partnership agreement.
Q:Is virology still a priority area of interest?
A:Virology is of lower priority compared to oncology and immunology/inflammatory disease, but it is not entirely ruled out.
Q:How does the company address potential delays in decision-making when collaborating with Gilead?
A:The company emphasizes a collaborative relationship with Gilead, prewiring processes to avoid delays, and leveraging an experienced team to handle complexity.
Q:What are the plans for the internal pipeline, specifically for 3667?
A:The company plans to evaluate data from Phase II studies early next year and consider partnering for Phase III development, as it may require expertise and resources they currently lack.
Q:What is the timeline for the cell therapy wind down process?
A:The wind down process is expected to conclude in Q1, subject to consultation with works council. The company is open to viable proposals during this period.
Q:How will the company ensure cost-effective acquisition of derisked programs?
A:The company plans to be financially disciplined, leveraging the environment and their deal funnel to find opportunities that create value, even if it takes additional time.
Q:What is the capacity for deal-making given ongoing development requirements?
A:The company has EUR 3.1 billion in cash and plans to reserve capacity for Phase IIb or Phase III development, potentially splitting requirements with Gilead.
Q:Will potential transactions bring in R&D capabilities?
A:The company is flexible, considering both acquiring teams with transactions or funding external parties to continue development.
Q:Has Gilead's involvement in the deal process increased?
A:The company focuses on future collaboration with Gilead for mutually aligned opportunities, emphasizing a can-do attitude and constructive relationship.
Q:What is the duration and focus of the Gilead partnership agreement?
A:The OLCA agreement has about 3.5 years remaining, focusing on Gilead's ability to opt into programs and joint business development opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1. Specific details on the types of opportunities in the deal funnel and their likelihood of success. 2. Clear metrics or KPIs for the Gilead partnership, such as ROI or asset progress. 3. Detailed plans for the internal pipeline beyond general intentions for 3667. 4. Specific strategies to address potential delays in decision-making with Gilead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Belgium
Chief
EUR cash
EUR income
EUR month
EUR share
Galapagos term
Officer
TYK
activity
adviser
alternative
building
buyer
capital
cash balance
cash equivalent
currency
deal
decision
development opportunity
dollar
employee
equivalent investment
euro
hundred
income month
intention
investment requirement
loss
month EUR
month result
obligation
opportunity value
proposal
rate
release
review
right
therapy EUR
wind
work council
GLPG Transcript
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals mixed signals: while there is a net profit and improved operating loss, total net revenues have significantly decreased. The Q&A section highlighted strategic uncertainties and lack of specific guidance, which could unsettle investors. The shareholder return plan and improved financial metrics are positive, but the overall sentiment remains neutral due to revenue decline and strategic ambiguities.
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call reveals several negative factors: significant financial impacts from the cell therapy wind-down, strategic reorganization costs, and currency exchange risks. Although there is a strong cash position and improved operating profit, the dependency on Gilead and lack of clear guidance on cost management raise concerns. The Q&A section highlights management's avoidance of specifics on cost reduction and breakeven timelines, adding uncertainty. These factors, combined with the strategic reorganization costs and potential financial challenges, suggest a negative stock price movement in the next two weeks.
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents mixed signals. Financial performance shows a decrease in cash and interest income, but strategic currency shifts and stable income from royalties are positives. The Q&A highlights a focus on strategic partnerships, particularly with Gilead, but lacks clarity on deal specifics and internal pipeline strategies. The absence of strong guidance or new partnership announcements tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Positive10-31
The earnings call presents a stable financial position with a significant cash reserve and a net profit, despite a high cash burn rate. The strategic partnerships and regulatory progress in CAR-T therapies, along with a focus on oncology and immunology, are positive indicators. The Q&A reveals confidence in addressing potential therapy side effects and ongoing business development. However, some concerns remain about competitive pressures and logistical challenges. Overall, the sentiment is positive, with potential for stock price growth driven by strategic advancements and strong cash management.
GLPG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
